Intellia and ONK Collaborate on CRISPR-Edited Cancer Cell Therapies
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 2 (Table of Contents)
Published: 18 Feb-2022
DOI: 10.3833/pdr.v2022.i2.2672 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Intellia Therapeutics and ONK Therapeutics have entered into a licensing and collaboration agreement to advance allogenic CRISPR-edited natural killer (NK) cell therapies for the treatment of patients with cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS